Danette Daniels

Danette Daniels is a Vice President of the Protein Degrader Platform at Foghorn Therapeutics developing therapeutic degraders in the areas of chromatin regulation and oncology. She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics of degradation, understanding mechanism of action, and co-developing a new PROTAC modality. She is the 2026 Chair-Elect of the AACR Chemistry in Cancer Research group and co-Chair of the inaugural 2026 Induced Proximity Modalities and Therapeutics Gordon Research Conference. In February of 2023 she co-founded the Women in TPD and Induced Proximity Initiative which has over 1000 members and offers a mentorship program in addition to conference travel scholarships to early career scientists. Prior to Foghorn Therapeutics, she received her PhD in Biophysics at Yale University, was a postdoctoral fellow at Stanford School of Medicine studying the Wnt signaling pathway, and a Group Leader at Promega Corporation.